TrialPloS one2022

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.

Viki Bockstal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.